Arrowhead Clinic is excited to introduce a new range of services that focus on car accident injuries, providing patients in ...

Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.

Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025 MIAMI, FL / ACCESS Newswire / August 19, 2025 / MIRA Pharmaceuticals, Inc.

Arrowhead Clinic in Garden City is excited to announce a new resource available on their WordPress site detailing advanced ...

Preliminary data are expected this year for a Phase 1/2 clinical trial testing the investigational therapy SRP-1003 in DM1.

We recently published 10 Double-Digit Winners You Wish You Bought Yesterday. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the last week’s top performers. Arrowhead Pharmaceuticals soared by ...

Last week, PureTech Health spun out a new company, Celea Therapeutics, which will develop its pulmonary fibrosis candidate ...

Arrowhead Pharmaceuticals stock tumbled Thursday after Sarepta Therapeutics liquefied its entire stake in the smaller biotech ...

Sarepta stock has been in free fall since safety issues derailed Elevidys, a gene therapy analysts had expected to achieve ...

The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with ...

Liquidating its stake in Arrowhead helps Sarepta cover a milestone payment and secure what one analyst described as ...

Sarepta will sell back $50 million worth of shares to cover part of a $100 million milestone payment and its remaining shares worth $174 million.